Plasma Homocysteine after Insulin Infusion in Type II Diabetic Patients with and without Methionine Intolerance

Abstract

Background

A high prevalence of hyperhomocysteinemia has been reported in type II diabetic patients with documented vascular disease; hence the hypothesis that hyperhomocysteinemia may contribute to overall mortality in diabetic patients. The link between insulin and homocysteine metabolism has not been completely clarified yet; in particular, only few data are available on the effects of insulin in vivo on homocysteine metabolism in the presence of abnormalities of sulphur amino acid metabolism (methionine intolerance).

Materials and Methods

To establish whether methionine intolerance and which of its determinants could influence total plasma homocysteine in response to insulin infusion in vivo in type II diabetic patients, we submitted 18 patients (Group A) with normal and 18 patients with abnormal (hyperhomocysteinemia) (Group B) response to oral methionine load to a glucose/clamp study. At time 0, and 30, 60 and 120 minutes after hyperinsulinemia, homocysteine and methionine plasma levels were assessed. In order to evaluate the cause of methionine intolerance, all patients were assayed for fasting homocysteine-cysteine ratio (as a marker of suspected heterozygosis for cystathionine-β-synthase deficit), MTHFR C₆₇₇T status and homocysteine-related vitamin status (serum vitamin B₆ [PLP], vitamin B₁₂ and folate).

Results

After hyperinsulinemia, plasma methionine was reduced (by about - 30 % at 120 minutes vs. basal values) within both groups, whereas tHcy tend to decrease in group A following insulin administration (up to - 6.6 ± 3.6 % vs. basal values at 120 minutes) with a significantly higher variability, while in patients with “methionine intolerance” (group B) tHcy tended to increase (up to + 29.05 ± 8.3 % vs. basal values at 120 min from the clamp). Serum folic acid (7.45 ± 2.8 vs. 4.82 ± 2.5 nmol/L, p < 0.05), Vit. B₁₂ (348 ± 78 vs. 242 ± 65 pmol/L, p < 0.05) and PLP (84.1 ± 23.6 vs. 50.6 ± 32.4 nmol/L; p < 0.01) were significantly higher in group A than in group B; PLP levels significantly correlated with homocysteine after 4 h methionine load (n = 36; r = - 0.327, p < 0.05); group A showed also a significantly lower prevalence of suspected heterozygosis for cystathionine-β-synthase deficit (1/18 [11.1 %] vs. 5/18 [33.3 %], p < 0.05) and MTHFR T allele presence (4/18 [22.2 %] vs. 11/18 [61.1 %], p < 0.01).

A stepwise regression analysis with tHcy plasma level variations (event A = reduction; event B = increase) as the dependent variable showed that low serum folate and PLP levels and presence of MTHFR T allele were the variables associated with insulin-induced tHcy increase.

Conclusions

Methionine intolerance may influence the effect of insulin administration on plasma homocysteine in patients affected by type 2 diabetes. To prevent a possible acute (and repeated) hyperhomocysteinemia due to insulin administration in cases of methionine intolerance, it may be useful to assess the presence of methionine intolerance (tHcy after oral methionine loading) and Hcy-related vitamin status in all patients due to be subjected to insulin therapy.

Homocysteine - methionine intolerance - diabetes - transsulfuration - homocysteine/cysteine ratio - vitamin B₆ - insulin

References

• 1 Arnesen E, Refsum H, Bonaa K H, Ueland P M, Forde O H, Nordrehaug J E. Serum total homocysteine and coronary heart disease.  Int J Epidemiol. 1995;  24 704-709
• 2 Bailey A L, Wright A J, Southon S. High performance liquid chromatography method for the determination of pyridoxal-5-phosphate in human plasma: how appropriate are cut-off values for vitamin B6 deficiency?.  Eur J Clin Nutr. 1999;  53 448-455
• 3 Beylot M, Chambrier C, Moneger A, Cohen R. Effects of small variations in insulin and glucagon levels on plasma aminoacids concentrations.  Diabete Metab. 1989;  15 38-44
• 4 Blom H J. Genetic determinants of hyperhomocysteinaemia: the roles of cystathionine beta-synthase and 5, 10-methylenetetrahydrofolate reductase.  Eur J Pediatr. 2000;  159 (Suppl 3) S208-212
• 5 Blom H J, Verhoef D P. Hyperhomocysteinemia, MTHFR, and risk of vascular disease.  Circulation. 2000;  101 E171-discussion E173
• 6 Boddie A M, Steen M T, Sullivan K M, Pasquali M, Dembure P P, Coates R J, Elsas II. L J. Cystathionine-beta-synthase deficiency: detection of heterozygotes by the ratios of homocysteine to cysteine and folate.  Metabolism. 1998;  47 207-211
• 7 Boers G H, Smals A G, Trijbels F J, Fowler B, Bakkeren J A, Schoonderwaldt H C, Kleijer W J, Kloppenborg P W. Heterozygosity for homocystinuria in premature peripheral and cerebral occlusive arterial disease.  N Engl J Med. 1985;  313 709-715
• 8 Bostom A G, Jacques P F, Nadeau M R, Williams R R, Ellison R C, Selhub J. Post-methionine load hyperhomocysteinemia in persons with normal fasting total plasma homocysteine: initial results from the NHLBI Family Heart Study.  Atherosclerosis. 1995;  116 147-151
• 9 Boushey C J, Beresford S A, Omenn G S, Motulsky A G. A quantitative assessment of plasma homocysteine as a risk factor for vascular disease. Probable benefits of increasing folic acid intakes.  JAMA. 1995;  274 1049-1057
• 10 Brattstrom L, Israelsson B, Norrving B, Bergqvist D, Thorne J, Hultberg B, Hamfelt A. Impaired homocysteine metabolism in early-onset cerebral and peripheral occlusive arterial disease. Effects of pyridoxine and folic acid treatment.  Atherosclerosis. 1990;  81 51-60
• 11 Brattstrom L, Lindgren A, Israelsson B, Malinow M R, Norrving B, Upson B, Hamfelt A. Hyperhomocysteinaemia in stroke: prevalence, cause, and relationships to type of stroke and stroke risk factors.  Eur J Clin Invest. 1992;  22 214-221
• 12 Carlsen S M, Folling I, Grill V, Bjerve K S, Schneede J, Refsum H. Metformin increases total serum homocysteine levels in non-diabetic male patients with coronary heart disease.  Scand J Clin Lab Invest. 1997;  57 521-527
• 13 Clarke R, Daly L, Robinson K, Naughten E, Cahalane S, Fowler B, Graham I. Hyperhomocysteinemia: an independent risk factor for vascular disease.  N Engl J Med. 1991;  324 1149-1155
• 14 Cornwell P E, Morgan S L, Vaughn W H. Modification of a high-performance liquid chromatographic method for assay of homocysteine in human plasma.  J Chromatogr. 1993;  617 136-139
• 15 Coull B M, Malinow M R, Beamer N, Sexton G, Nordt F, de Garmo P. Elevated plasma homocyst(e)ine concentration as a possible independent risk factor for stroke.  Stroke. 1990;  21 572-576
• 16 Cronin C C, McPartlin J M, Barry D G, Ferriss J B, Scott J M, Weir D G. Plasma homocysteine concentrations in patients with type 1 diabetes.  Diabetes Care. 1998;  21 1843-1847
• 17 de Jong S C, Stehouwer C D, Mackaay A J, van den Berg M, Bulterijs E J, Visser F C, Bax J, Rauwerda J A. High prevalence of hyperhomocysteinemia and asymptomatic vascular disease in siblings of young patients with vascular disease and hyperhomocysteinemia.  Arterioscler Thromb Vasc Biol. 1997;  17 2655-2662
• 18 de Jong S C, Stehouwer C D, van den Berg M, Kostense P J, Alders D, Jakobs C, Pals G, Rauwerda J A. Determinants of fasting and post-methionine homocysteine levels in families predisposed to hyperhomocysteinemia and premature vascular disease.  Arterioscler Thromb Vasc Biol. 1999;  19 1316-1324
• 19 Domagala T B, Libura M, Szczeklik A. Hyperhomocysteinemia following oral methionine load is associated with increased lipid peroxidation.  Thromb Res. 1997;  87 411-416
• 20 Drzewoski J, Czupryniak L, Chwatko G, Bald E. Total plasma homocysteine and insulin levels in type 2 diabetic patients with secondary failure to oral agents.  Diabetes Care. 1999;  22 2097-2099
• 21 Engbersen A M, Franken D G, Boers G H, Stevens E M, Trijbels F J, Blom H J. Thermolabile 5, 10-methylenetetrahydrofolate reductase as a cause of mild hyperhomocysteinemia.  Am J Hum Genet. 1995;  56 142-150
• 22 Fonseca V A, Mudaliar S, Schmidt B, Fink L M, Kern P A, Henry R R. Plasma homocysteine concentrations are regulated by acute hyperinsulinemia in nondiabetic but not type 2 diabetic subjects.  Metabolism. 1998;  47 686-689
• 23 Fortin L J, Genest Jr J. Measurement of homocyst(e)ine in the prediction of arteriosclerosis.  Clin Biochem. 1995;  28 155-162
• 24 Frosst P, Blom H J, Milos R, Goyette P, Sheppard C A, Matthews R G, Boers G J, den Heijer M, Kluijtmans L A, van den Heuvel L P. et al . A candidate genetic risk factor for vascular disease: a common mutation in methylenetetrahydrofolate reductase.  Nat Genet. 1995;  10 111-113
• 25 Glanville N T, Anderson G H. Altered methionine metabolism in streptozotocin-diabetic rats.  Diabetologia. 1984;  27 468-471
• 26 Graham I M, Daly L E, Refsum H M, Robinson K, Brattstrom L E, Ueland P M, Palma-Reis R J, Boers G H, Sheahan R G, Israelsson B, Uiterwaal C S, Meleady R, McMaster D, Verhoef P, Witteman J, Rubba P, Bellet H, Wautrecht J C, de Valk H W, Sales Luis A C, Parrot-Rouland F M, Tan K S, Higgins I, Garcon D, Andria G. et al . Plasma homocysteine as a risk factor for vascular disease. The European Concerted Action Project.  JAMA. 1997;  277 1775-1781
• 27 Guttormsen A B, Ueland P M, Nesthus I, Nygard O, Schneede J, Vollset S E, Refsum H. Determinants and vitamin responsiveness of intermediate hyperhomocysteinemia (> or = 40 micromol/liter). The Hardaland Homocysteine Study.  J Clin Invest. 1996;  98 2174-2183
• 28 Harker L A, Ross R, Slichter S J, Scott C R. Homocystine-induced arteriosclerosis. The role of endothelial cell injury and platelet response in its genesis.  J Clin Invest. 1976;  58 731-741
• 29 Harmon D L, Woodside J V, Yarnell J W, McMaster D, Young I S, McCrum E E, Gey K F, Whitehead A S, Evans A E. The common ‘thermolabile’ variant of methylene tetrahydrofolate reductase is a major determinant of mild hyperhomocysteinaemia.  QJM. 1996;  89 571-577
• 30 Hoogeveen E K, Kostense P J, Beks P J, Mackaay A J, Jakobs C, Bouter L M, Heine R J, Stehouwer C D. Hyperhomocysteinemia is associated with an increased risk of cardiovascular disease, especially in non-insulin-dependent diabetes mellitus: a population-based study.  Arterioscler Thromb Vasc Biol. 1998;  18 133-138
• 31 Hoogeveen E K, Kostense P J, Jakobs C, Dekker J M, Nijpels G, Heine R J, Bouter L M, Stehouwer C D. Hyperhomocysteinemia increases risk of death, especially in type 2 diabetes: 5-year follow-up of the Hoorn Study.  Circulation. 2000;  101 1506-1511
• 32 Hultberg B, Agardh C D, Agardh E, Lovestam-Adrian M. Poor metabolic control, early age at onset, and marginal folate deficiency are associated with increasing levels of plasma homocysteine in insulin-dependent diabetes mellitus. A five-year follow-up study.  Scand J Clin Lab Invest. 1997;  57 595-600
• 33 Jacques P F, Bostom A G, Williams R R, Ellison R C, Eckfeldt J H, Rosenberg I H, Selhub J, Rozen R. Relation between folate status, a common mutation in methylenetetrahydrofolate reductase, and plasma homocysteine concentrations.  Circulation. 1996;  93 7-9
• 34 Kang S S, Wong P W, Malinow M R. Hyperhomocyst(e)inemia as a risk factor for occlusive vascular disease.  Annu Rev Nutr. 1992;  12 279-298
• 35 Katz A, Nambi S S, Mather K, Baron A D, Follmann D A, Sullivan G, Quon M J. Quantitative insulin sensitivity check index: a simple, accurate method for assessing insulin sensitivity in humans.  J Clin Endocrinol Metab. 2000;  85 2402-2410
• 36 Kluijtmans L A, van den Heuvel L P, Boers G H, Frosst P, Stevens E M, van Oost B A, den Heijer M, Trijbels F J, Rozen R, Blom H J. Molecular genetic analysis in mild hyperhomocysteinemia: a common mutation in the methylenetetrahydrofolate reductase gene is a genetic risk factor for cardiovascular disease.  Am J Hum Genet. 1996;  58 35-41
• 37 Lanfredini M, Fiorina P, Peca M G, Veronelli A, Mello A, Astorri E, Dall'Aglio P, Craveri A. Fasting and post-methionine load homocyst(e)ine values are correlated with microalbuminuria and could contribute to worsening vascular damage in non-insulin-dependent diabetes mellitus patients.  Metabolism. 1998;  47 915-921
• 38 Loscalzo J. The oxidant stress of hyperhomocyst(e)inemia.  J Clin Invest. 1996;  98 5-7
• 39 Luzi L, Petrides A S, De Fronzo R A. Different sensitivity of glucose and amino acid metabolism to insulin in NIDDM.  Diabetes. 1993;  42 1868-1877
• 40 Malinow M R. Hyperhomocyst(e)inemia. A common and easily reversible risk factor for occlusive atherosclerosis.  Circulation. 1990;  81 2004-2006
• 41 Mason J B, Miller J W. The effects of vitamins B12, B6, and folate on blood homocysteine levels.  Ann N Y Acad Sci. 1992;  669 197-203 discussion 203-194
• 42 Miller J W, Ribaya-Mercado J D, Russell R M, Shepard D C, Morrow F D, Cochary E F, Sadowski J A, Gershoff S N, Selhub J. Effect of vitamin B-6 deficiency on fasting plasma homocysteine concentrations.  Am J Clin Nutr. 1992;  55 1154-1160
• 43 Morrow L E, Grimsley E W. Long-term diuretic therapy in hypertensive patients: effects on serum homocysteine, vitamin B6, vitamin B12, and red blood cell folate concentrations.  South Med J. 1999;  92 866-870
• 44 Mudd S HLH. Disorders in transsulfuration. Stanbury JBWJ, Fredrickson DS, Goldstein JL, Brown MS Metabolic Bases of Inherited Diseases. 5th ed. New York; McGraw-Hill Book Co 1995: 1279-1327
• 45 Munshi M N, Stone A, Fink L, Fonseca V. Hyperhomocysteinemia following a methionine load in patients with non-insulin-dependent diabetes mellitus and macrovascular disease.  Metabolism. 1996;  45 133-135
• 46 Olszewski A J, McCully K S. Homocysteine metabolism and the oxidative modification of proteins and lipids.  Free Radic Biol Med. 1993;  14 683-693
• 47 Ou K, Wilkins M R, Yan J X, Gooley A A, Fung Y, Sheumack D, Williams K L. Improved high-performance liquid chromatography of amino acids derivatised with 9-fluorenylmethyl chloroformate.  J Chromatogr A. 1996;  723 219-225
• 48 Pijl H, Potter van Loon B J, Toornvliet A C, Radder J K, Onkenhout W, Frolich M, Meinders A E. Insulin-induced decline of plasma amino acid concentrations in obese subjects with and without non-insulin-dependent diabetes.  Metabolism. 1994;  43 640-646
• 49 Refsum H, Ueland P M. Clinical significance of pharmacological modulation of homocysteine metabolism.  Trends Pharmacol Sci. 1990;  11 411-416
• 50 Reis R P, Azinheira J, Reis H P, Bordalo A, Santos L, Adao M, Pina J E, Ferreira N C, Luis A S. Homocysteinaemia after methionine overload as a coronary artery disease risk factor: importance of age and homocysteine levels.  Coron Artery Dis. 1995;  6 851-856
• 51 Report of the Expert Committee on the Diagnosis and Classification of Diabetes Mellitus . .  Diabetes Care. 2000;  23 (Suppl 1) S4-19
• 52 Robillon J F, Canivet B, Candito M, Sadoul J L, Jullien D, Morand P, Chambon P, Freychet P. Type 1 diabetes mellitus and homocyst(e)ine.  Diabete Metab. 1994;  20 494-496
• 53 Rozen R. Genetic predisposition to hyperhomocysteinemia: deficiency of methylenetetrahydrofolate reductase (MTHFR).  Thromb Haemost. 1997;  78 523-526
• 54 Selhub J, Miller J W. The pathogenesis of homocysteinemia: interruption of the coordinate regulation by S-adenosylmethionine of the remethylation and transsulfuration of homocysteine.  Am J Clin Nutr. 1992;  55 131-138
• 55 Stampfer M J, Malinow M R, Willett W C, Newcomer L M, Upson B, Ullmann D, Tishler P V, Hennekens C H. A prospective study of plasma homocyst(e)ine and risk of myocardial infarction in US physicians.  JAMA. 1992;  268 877-881
• 56 Swendseid M E, Tuttle S G, Drenick E J, Joven C B, Massey F J. Plasma amino acid response to glucose administration in various nutritive states.  Am J Clin Nutr. 1967;  20 243-249
• 57 Tsai M Y, Garg U, Key N S, Hanson N Q, Suh A, Schwichtenberg K. Molecular and biochemical approaches in the identification of heterozygotes for homocystinuria.  Atherosclerosis. 1996;  122 69-77
• 58 Tsai M Y, Welge B G, Hanson N Q, Bignell M K, Vessey J, Schwichtenberg K, Yang F, Bullemer F E, Rasmussen R, Graham K J. Genetic causes of mild hyperhomocysteinemia in patients with premature occlusive coronary artery diseases.  Atherosclerosis. 1999;  143 163-170
• 59 van den Berg M, Franken D G, Boers G H, Blom H J, Jakobs C, Stehouwer C D, Rauwerda J A. Combined vitamin B6 plus folic acid therapy in young patients with arteriosclerosis and hyperhomocysteinemia.  J Vasc Surg. 1994;  20 933-940
• 60 van den Berg M, Stehouwer C D, Bierdrager E, Rauwerda J A. Plasma homocysteine and severity of atherosclerosis in young patients with lower-limb atherosclerotic disease.  Arterioscler Thromb Vasc Biol. 1996;  16 165-171
• 61 Ventura P, Panini R, Verlato C, Scarpetta G, Salvioli G. Peroxidation indices and total antioxidant capacity in plasma during hyperhomocysteinemia induced by methionine oral loading.  Metabolism. 2000;  49 225-228
• 62 Wall R T, Harlan J M, Harker L A, Striker G E. Homocysteine-induced endothelial cell injury in vitro: a model for the study of vascular injury.  Thromb Res. 1980;  18 113-121
• 63 Welch G N, Upchurch Jr G. Loscalzo J. Hyperhomocyst(e)inemia and atherothrombosis.  Ann N Y Acad Sci. 1997 a;  811 48-58 discussion 58-49
• 64 Welch G N, Upchurch Jr G R. Loscalzo J. Homocysteine, oxidative stress, and vascular disease.  Hosp Pract (Off Ed). 1997 b;  32 81-92
• 65 Wilcken D E, Wilcken B, Dudman N P, Tyrrell P A. Homocystinuria - the effects of betaine in the treatment of patients not responsive to pyridoxine.  N Engl J Med. 1983;  309 448-453
• 66 Zinneman H H, Nuttall F Q, Goetz F C. Effect of endogenous insulin on human amino acid metabolism.  Diabetes. 1966;  15 5-8